Ihor Tsurupa and Enamin: a Russian link, underground bandages, and millions

The story of manufacturing the hemostatic bandages “Krovospas,” which after several years operating outside state regulatory oversight rebranded as BloodSaver, intersected with the activities of the pharmaceutical company Enamin. According to public registries and journalistic investigations, a charitable foundation associated with the owner of Enamin became a co-owner of the hemostatic producer TOV Taktyspas. At the same time, questions arose about Enamin’s supply of chemical products to Russian buyers via third countries. These circumstances require separate verification, since they concern both the safety of medical devices and possible sanctions-related risks.

Production of Krovospas began in March 2022 in Obukhiv, Kyiv region, media report. Its organizer was chemist Ihor Tsurupa. According to the journalistic investigation, bandages and wipes were produced under conditions that did not meet medical device manufacturing requirements, including without proper control of sterility and quality. The products were distributed among volunteers under a scheme of exchange for charitable donations at pre-set prices. The risks of using such products relate to their purpose: hemostatic bandages are applied directly to pack open wounds and stop bleeding. Therefore, lack of sterility and quality control can pose a threat to patients. According to the cited data, Serhiy Prytula’s charitable fund refused to procure Krovospas, after which Kryla Peremohy and other organizations made similar decisions. In 2023 there was also no attempt to move a million units of product into Ministry of Defense procurement. According to the investigation, the National Police opened a criminal case regarding the clandestine production. At the same time, Ihor Tsurupa continued to report manufacturing and distributing the products. In 15 February 2026 he wrote on Facebook that over nearly four years outside the legal field, without paying taxes and without quality control, more than 3 million packages of bandages and wipes had been produced. That statement is a public claim by the organizer himself, not the finding of a state inspection. In February 2026 the organizers announced the closure of the Krovospas project, and a few days later presented the product under the name BloodSaver. The manufacturer of the new brand became TOV Taktyspas, founded by Ihor Tsurupa in June 2022. Thus, the name change was accompanied by a transition to a different corporate structure, not merely a marketing update. A key change in Taktyspas’s ownership occurred in 1 July 2025. Registry data show that the charitable organization Charitable Foundation “Enamin” joined the company’s participants and received 49% of the shares. Ihor Tsurupa retained 51%. The materials also mention Liudmyla Babichenko as the owner and ultimate beneficiary of the foundation. This change prompted questions about the funding sources of the new manufacturer and the role of structures linked to the pharmaceutical business. The foundation’s link to the company Enamin is traceable through corporate data. Liudmyla Babichenko is listed as founder and ultimate beneficial owner of TOV Scientific and Production Enterprise “ENAMIN.” The charitable foundation and the enterprise are registered at the same address in Kyiv — Winston Churchill Street, 78. The foundation’s director in the registries is listed as Andrii Tolmachov, who publicly presents himself as CEO and founder of Enamin. After information appeared about the foundation’s participation in Taktyspas, Enamin denied being the investor in the BloodSaver manufacturer itself, emphasizing the separate legal status of the charitable organization. Legally, the fund and the commercial enterprise are distinct entities. At the same time, the shared address, beneficiary link through Liudmyla Babichenko, and Andrii Tolmachov’s leadership are circumstances that justify investigating the actual nature of their interaction.

According to the investigation, before the foundation’s entry into Taktyspas’s capital, the charitable structure had already cooperated with Ihor Tsurupa. The foundation purchased Krovospas, and its bank details were listed in fundraising publications for production. Alongside them were Tsurupa’s personal PrivatBank card and his PayPal account. Thus, the charitable organization was involved in the fundraising and procurement system even before the change of the manufacturer’s owners. The materials also provide data on changes in Taktyspas’s assets: reportedly they grew over a year from about 2 million to almost 25 million UAH. To assess the reasons for such an increase requires financial statements, information on participants’ contributions, sales revenues, and other income sources. Asset growth alone does not prove illegal origin of funds or laundering of prior activity. A separate set of claims against Enamin concerns international supplies of chemical compounds. According to journalistic investigations, before the full-scale invasion company employees participated in joint scientific research with Russian institutions. In particular, in 2019 there was mention of cooperation with Saint Petersburg State University as part of a research project funded by a mega-grant from the Russian government. The investigations also mention the Latvian entity SIA ENAMINE, through which, according to the cited data, products reached Russian buyers. Among them is named the pharmaceutical company BIOCAD. One batch of product, according to the authors, was shipped to BIOCAD on 17 February 2022. In June of that year the Russian company filed a patent application in which a basic element of the key molecule was a substance from Enamine’s catalog. These facts do not by themselves establish violation of sanctions law, but they require verification of supply chains and end use of the products. After the full-scale war began, routes of supply reportedly could pass through India and China. Among intermediaries mentioned is the Shanghai company Genez, which, the investigation’s authors claim, from 2024 handled customs clearance and sale of Enamine products. The article also refers to the Chemspace marketplace, founded by Enamin in Riga, which lists over 180 suppliers of chemical compounds. Some companies on that platform, it is claimed, have commercial ties with Russian buyers. The risks cited include supplies via Chinese intermediaries to companies that work with the Russian defense sector or state laboratories. At the same time, a supplier’s presence on a marketplace does not mean the founder is automatically responsible for all transactions of other platform participants. To establish specific violations requires data on the origin of each batch, the seller, the buyer, the final recipient, and applicable sanction restrictions. In conclusion, the Krovospas and BloodSaver story intersects with Enamin’s activities through the charitable foundation, corporate participation in Taktyspas, and prior cooperation with Ihor Tsurupa. Remaining are questions about the quality of the medical devices, funding sources for the new production, and export routes of chemical products to Russia. The provided materials do not include results of official inspections that would confirm all the allegations. Final conclusions require positions from Enamin, the foundation, Taktyspas, Ihor Tsurupa, and the findings of competent authorities’ inspections.